{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:12Z","timestamp":1753891932060,"version":"3.41.2"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Trisomy 21 (Down syndrome) is a chromosomal disorder associated with humoral and cellular immunologic impairments among other systemic manifestations. It occurs at a frequency of 1 in 750 live births. There are increasing reports of children with Down syndrome presenting signs of severe COVID-19. The literature from Africa on pediatric COVID-19 and risk stratification for severe disease is scant. A summary of the clinical features, complications, and treatment outcomes of three Ethiopian children with Trisomy 21 and severe COVID-19 along with a discussion of the correlation between trisomy 21 immunology and severe SARS CoV-2 infection is presented.<\/jats:p>","DOI":"10.3389\/fped.2022.991142","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T05:59:17Z","timestamp":1665640757000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Children with trisomy 21 are a group at risk for severe COVID-19: Case reports from a COVID-19 treatment unit in Addis Ababa, Ethiopia"],"prefix":"10.3389","volume":"10","author":[{"given":"Tinsae","family":"Alemayehu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danilo","family":"Buonsenso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100769","article-title":"Medical vulnerability of individuals with down syndrome to severe COVID-19 \u2013 data from the trisomy 21 research society and the UK ISARIC4C survey.","volume":"33","author":"Huls","year":"2021","journal-title":"Eclin Med."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10215125","article-title":"COVID-19 in children with down syndrome: data from the trisomy 21 research society survey.","volume":"10","author":"Emes","year":"2021","journal-title":"J Clin Med."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-020-02471-5","article-title":"COVID-19 and children with Down syndrome: is there any real reason to worry? Two case reports with severe course.","volume":"20","author":"Kantar","year":"2020","journal-title":"BMC Pediatr."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2021.6436","article-title":"Assessment of clinical outcomes among children and adolescents hospitalized with COVID-19 in 6 sub-saharan African Countries.","volume":"176","author":"Nachega","year":"2022","journal-title":"JAMA Pediatr."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01719-2","article-title":"Epidemiological and clinical features of pediatric COVID-19.","volume":"18","author":"Guo","year":"2020","journal-title":"BMC Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/jpids\/piaa074","article-title":"The epidemiology of severe acute respiratory syndrome coronavirus 2 in a pediatric healthcare network in the United States.","volume":"9","author":"Otto","year":"2020","journal-title":"J Pediatr Infect Dis Soc."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-009399","article-title":"COVID-19 disease severity risk factors for pediatric patients in Italy.","volume":"146","author":"Bellino","year":"2020","journal-title":"Pediatrics."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1097\/INF.0000000000003043","article-title":"Risk factors for severe COVID-19 in children.","volume":"40","author":"Graff","year":"2022","journal-title":"Pediatr Infect Dis J."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-053418","article-title":"Risk factors for severe COVID-19 in children.","volume":"149","author":"Woodruff","year":"2022","journal-title":"Pediatrics."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.11182","article-title":"Underlying medical conditions associated with severe COVID-19 illness among children.","volume":"4","author":"Kompaniyets","year":"2021","journal-title":"JAMA Netw Open."},{"key":"B11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2249.2011.04335.x","article-title":"Infections and immunodeficiency in down syndrome.","volume":"164","author":"Ram","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-020-00453-4","article-title":"Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis.","volume":"8","author":"Huang","year":"2020","journal-title":"J Intensive Care."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.621440","article-title":"Immune dysregulation and the increased risk of complications and mortality following respiratory tract infections in adults with down syndrome.","volume":"12","author":"Tomer","year":"2021","journal-title":"Front Immunol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V108.11.1489.1489","article-title":"Down syndrome as an independent risk factor for Thrombosis in children.","volume":"108","author":"Journeycake","year":"2006","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100850","article-title":"An autopsy study of the spectrum of severe COVID-19 in children: from SARS to different phenotypes of MIS-C.","volume":"35","author":"Duarte-Neto","year":"2021","journal-title":"EClin Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1097\/inf.0000000000003227","article-title":"Clinical characteristics and histopathology of coronavirus disease 2019-related deaths in African children.","volume":"40","author":"Mabena","year":"2021","journal-title":"Pediatr Infect Dis J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.pcl.2020.07.014","article-title":"Risk factors for severity in children with coronavirus disease 2019: a comprehensive literature review.","volume":"68","author":"Tsabouri","year":"2021","journal-title":"Pediatr Clin North Am."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1001\/jama.2020.4683","article-title":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy.","volume":"323","author":"Onder","year":"2020","journal-title":"JAMA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0140-6736(21)00799-6","article-title":"Characterization of in-hospital complications associated with COVID-19 using the ISARIC WHO clinical characterization protocol UK: a prospective, multi-center cohort study.","volume":"398","author":"Drake","year":"2021","journal-title":"Lancet."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-056726","article-title":"COVID-19 anticoagulation in children \u2013 thromboprophylaxis (COVAC-TP) trial investigators; enoxaparin thromboprophylaxis in children hospitalized for COVID-19: a phase 2 trial.","volume":"150","author":"Sochet","year":"2022","journal-title":"Pediatrics."},{"key":"B21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1182\/blood.2020010218","article-title":"Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C.","volume":"138","author":"Whitworth","year":"2021","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29049","article-title":"How we approach thrombosis risk in children with COVID-19 infection and MIS-C.","volume":"68","author":"Sharathkumar","year":"2021","journal-title":"Pediatr Blood Cancer"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.991142\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T05:59:19Z","timestamp":1665640759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.991142\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":22,"alternative-id":["10.3389\/fped.2022.991142"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.991142","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2022,10,13]]},"article-number":"991142"}}